ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 2.22 USD 9.36% Market Closed
Market Cap: 214.7m USD
Have any thoughts about
ADC Therapeutics SA?
Write Note

P/E
Price to Earnings

-0.6
Current
-1.2
Median
22.7
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-0.6
=
Market Cap
214.6m USD
/
Net Income
-367.2m USD
All Countries
Close
Market Cap P/E
CH
ADC Therapeutics SA
NYSE:ADCT
214.6m USD -0.6
FR
Pharnext SCA
OTC:PNEXF
6T USD -179 646.3
US
Abbvie Inc
NYSE:ABBV
320.1B USD 63
US
Amgen Inc
NASDAQ:AMGN
147.4B USD 34.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD -248.8
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD 903.4
US
Epizyme Inc
F:EPE
94.1B EUR -475.6
AU
CSL Ltd
ASX:CSL
135.4B AUD 33.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 17.8
US
Seagen Inc
F:SGT
39.3B EUR -55.1
NL
argenx SE
XBRU:ARGX
34.3B EUR -130
Earnings Growth
CH
ADC Therapeutics SA
NYSE:ADCT
Average P/E: 210.4
Negative Multiple: -0.6
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -179 646.3 N/A
US
Abbvie Inc
NYSE:ABBV
63
412%
US
Amgen Inc
NASDAQ:AMGN
34.9
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -248.8
42%
US
Gilead Sciences Inc
NASDAQ:GILD
903.4
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -475.6 N/A
AU
CSL Ltd
ASX:CSL
33.1
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.1 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-0.4
2-Years Forward
P/E
-0.3
3-Years Forward
P/E
-1.8

See Also

Discover More